RT Journal Article
T1 Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
A1 Sánchez-Muñoz, Alfonso
A1 Gallego-Domínguez, Elena María
A1 De Luque, Vanessa
A1 Pérez-Rivas, Luis G.
A1 Vicioso-Recio, Luis Prudencio
A1 Ribelles, Nuria
A1 Lozano-Castro, José
A1 Alba-Conejo, Emilio
K1 Cáncer - Aspectos genéticos
K1 Mamas - Cáncer - Aspectos genéticos
AB Background: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal growth factor receptor (EGFR) therapies. Assessment of the mutation status of KRAS might also be of potential relevance in other EGFR-overexpressing tumors,such as those occurring in breast cancer. Although KRAS is mutated in only a minor fraction of breast tumors (5%), about 60% of the basal-like subtype express EGFR and, therefore could be targeted by EGFR inhibitors. We aimed to study the mutation frequency of KRAS in that subtype of breast tumors to provide a molecular basis for the evaluation of anti-EGFR therapies.Methods: Total, genomic DNA was obtained from a group of 35 formalin-fixed paraffin-embedded, triple-negative breast tumor samples. Among these, 77.1% (27/35) were defined as basal-like by immunostaining specific for the established surrogate markers cytokeratin (CK) 5/6 and/or EGFR. KRAS mutational status was determined in the purified DNA samples by Real Time(RT)-PCR using primers specific for the detection of wild-type KRAS or the following seven oncogenic somatic mutations: Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp.Results: We found no evidence of KRAS oncogenic mutations in all analyzed tumors.Conclusions: This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR inabout 60% of all cases.
PB Springer Nature
YR 2010
FD 2010-04-13
LK https://hdl.handle.net/10630/29544
UL https://hdl.handle.net/10630/29544
LA eng
NO Sánchez-Muñoz A, Gallego E, de Luque V, Pérez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer. 2010 Apr 13;10:136. doi: 10.1186/1471-2407-10-136. PMID: 20385028; PMCID: PMC2868051.
NO Este artículo ha sido publicado en Annals of Oncology.Esta versión tiene Licencia Creative Commons CC-BY.
NO This work was supported by Fondo de Investigaciones Sanitarias grant PI081797 (to E. A.) and Ministerio de Ciencia e Innovación grant BFU2007- 66100 (to J. L.).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026